Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort

Rheumatology ◽

10.1093/rheumatology/kex457 ◽

2017 ◽

Vol 57 (4) ◽

pp. 619-624 ◽

Author(s):

Fariz Yahya ◽

Karl Gaffney ◽

Louise Hamilton ◽

Ellie Lonsdale ◽

Jane Leeder ◽

...

Keyword(s):

United Kingdom ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Tumour Necrosis Factor Inhibitor ◽

Predictors Of Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort: reply

Rheumatology Advances in Practice ◽

10.1093/rap/rky037 ◽

2018 ◽

Vol 2 (2) ◽

Author(s):

Fariz Yahya ◽

Karl Gaffney ◽

Louise Hamilton ◽

Ellie Lonsdale ◽

Jane Leeder ◽

...

Keyword(s):

United Kingdom ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Tumour Necrosis Factor Inhibitor ◽

Predictors Of Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Comment on: Tumour necrosis factor inhibitor survival and predictors of response in axial spondyloarthritis—findings from a United Kingdom cohort

Rheumatology Advances in Practice ◽

10.1093/rap/rky036 ◽

2018 ◽

Vol 2 (2) ◽

Author(s):

Wala Al Arashi ◽

Carlota Iñiguez Ubiaga ◽

Elizabeth M Hensor ◽

Katie Gaffney ◽

Jane Freeston ◽

...

Keyword(s):

United Kingdom ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Tumour Necrosis Factor Inhibitor ◽

Predictors Of Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis

Rheumatology ◽

10.1093/rheumatology/kes184 ◽

2012 ◽

Vol 51 (11) ◽

pp. 2020-2026 ◽

Author(s):

H. Canhao ◽

A. M. Rodrigues ◽

A. F. Mourao ◽

F. Martins ◽

M. J. Santos ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Comparative Effectiveness ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Predictors Of Response ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort

Rheumatology ◽

10.1093/rheumatology/keu255 ◽

2014 ◽

Vol 54 (1) ◽

pp. 152-156 ◽

Author(s):

D. Wallis ◽

A. Thavaneswaran ◽

N. Haroon ◽

R. Ayearst ◽

R. D. Inman

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Infection Risk ◽

Tumour Necrosis Factor Inhibitor ◽

Inhibitor Therapy ◽

Factor Inhibitor ◽

Observational Cohort ◽

Necrosis Factor

Download Full-text

Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis

Journal of Dermatological Treatment ◽

10.3109/09546634.2012.713460 ◽

2012 ◽

Vol 25 (1) ◽

pp. 61-62 ◽

Author(s):

Amy C. Foulkes ◽

Christopher E. M. Griffiths ◽

Hector Chinoy ◽

Richard B. Warren

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Axial Spondyloarthritis ◽

Tumour Necrosis Factor Inhibitor ◽

Inhibitor Therapy ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Faculty Opinions recommendation of Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1108991.565450 ◽

2008 ◽

Author(s):

Martin Aringer ◽

Alexander Kleymann

Keyword(s):

Rheumatoid Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Joint Damage ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Structural Joint ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

OP0201 A phase 3 study of the efficacy and safety of ixekizumab in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitor(s)

10.1136/annrheumdis-2017-eular.1576 ◽

2017 ◽

Author(s):

P Nash ◽

B Kirkham ◽

M Okada ◽

P Rahman ◽

B Combe ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inadequate Response ◽

Efficacy And Safety ◽

Phase 3 ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

AB0446 Physician-reported behaviours and treatment trends of tumour necrosis factor inhibitor use: cycling versus switching in five european countries: france, germany, italy, spain and the uk

10.1136/annrheumdis-2018-eular.2991 ◽

2018 ◽

Author(s):

J.R. Curtis ◽

E. Sullivan ◽

J. Kershaw ◽

S. Blackburn ◽

P. Mahajan ◽

...

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

European Countries ◽

Factor Inhibitor ◽

The Uk ◽

Treatment Trends ◽

Necrosis Factor

Download Full-text

FRI0098 Elevated multi-biomarker disease activity (MBDA) predicts relapses in ra patients in sustained remission tapering tumour necrosis factor inhibitor therapy- results from the randomized controlled retro study

10.1136/annrheumdis-2017-eular.4787 ◽

2017 ◽

Author(s):

J Rech ◽

M Hagen ◽

M Englbrecht ◽

J Haschka ◽

M Reiser ◽

...

Keyword(s):

Disease Activity ◽

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Tumour Necrosis Factor Inhibitor ◽

Inhibitor Therapy ◽

Sustained Remission ◽

Randomized Controlled ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text

Management with secukinumab of tumour necrosis factor inhibitor‐induced pulmonary sarcoidosis‐like reaction in a patient with psoriasis

Clinical and Experimental Dermatology ◽

10.1111/ced.14101 ◽

2019 ◽

Vol 45 (4) ◽

pp. 455-456 ◽

Author(s):

G. Eichhoff

Keyword(s):

Tumour Necrosis Factor ◽

Tumour Necrosis ◽

Pulmonary Sarcoidosis ◽

Tumour Necrosis Factor Inhibitor ◽

Factor Inhibitor ◽

Necrosis Factor

Download Full-text